Study of The Effects of Testosterone in Frail Elderly Men
Information source: Central Manchester and Manchester Children's University hospitals NHS Trust
Information obtained from ClinicalTrials.gov on December 31, 2007 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Frailty; Sarcopenia
Intervention: Transdermal testosterone gel (Testogel 1% ) (Drug); Matched transdermal placebo gel (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Central Manchester and Manchester Children's University hospitals NHS Trust Official(s) and/or principal investigator(s): Professor Frederick CW Wu, MD, FRCP, Principal Investigator, Affiliation: Central Manchester and Manchester Children's University Hospitals Trust & The University of Manchester Dr Martin Connolly, MD, FRCP, Principal Investigator, Affiliation: Central Manchester and Manchester Children's University Hospitals Trust Professor JA Oldham, PhD, Principal Investigator, Affiliation: The University of Manchester
Summary
The study aims to determine the effects of testosterone on muscle function, mobility,
activities of daily living and overall quality of life
Clinical Details
Official title: Study of The Effects of Testosterone on Muscle Function, Physical Performance, Body Composition and Quality of Life in Frail Elderly Men
Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Lower limb muscle strength at 6 months
Secondary outcome: Upper limb muscle strength at 6 monthsQuality of life at 6 months Total and regional lean body mass at 6 months Improvement in physical performance Bone Mineral Density
Detailed description:
Ageing-associated loss of muscle mass and strength is a major cause of physical frailty,
disability, morbidity and dependency in the elderly. This is associated with increased falls,
fractures, loss of mobility, restricted activities of daily living and increased utilisation
of healthcare resources. It is well known that serum testosterone levels fall with advancing
age and this may be an important cause for muscle wasting and weakness (sarcopenia).
Testosterone replacement increases muscle mass and improves muscle strength in young
hypogonadal men. In relatively healthy elderly men, some short-term studies have also shown
that testosterone can improve muscle strength. The potential beneficial effects of
testosterone supplementation on muscle strength and functional capacity of frail elderly men
has so far not been studies and forms the basis of this research. We hypothesise that
testosterone supplementation is an effective, safe and economic anabolic intervention in
frail elderly men with low circulating testosterone.
Eligibility
Minimum age: 65 Years.
Maximum age: N/A.
Gender(s): Male.
Criteria:
Inclusion Criteria:
Frail elderly men (as defined by Freid's criteria of frailty)
Community - dwelling men aged 65 years and above
Total testosterone ≤12. 0 nmol/L or calculated free T≤0. 25nmol/L
Exclusion Criteria:
Carcinoma of prostate
Carcinoma of breast
PSA >4ng/mL
Severe symptomatic benign prostatic hypertrophy (IPSS >21)
Active liver disease
Renal impairment (serum creatinine >180 mmol/L)
Congestive heart failure
Unstable ischaemic heart disease
Polycythaemia
Evidence of systemic disease which may affect muscle/joint function
Moderate to severe peripheral vascular disease
Moderate to severe chronic obstructive airways disease
Alcohol consumption over 30 units per week
Medications that interfere with sex steroid metabolism
History of stroke causing persistent motor deficit
Cognitive deficit
Major psychiatric illness
Hospital admission in the past 6 weeks
Sleep apnoea
Locations and Contacts
Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary, Manchester M13 9WL, United Kingdom
Additional Information
Related publications: Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. Deslypere JP, Vermeulen A. Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab. 1984 Nov;59(5):955-62. Clague JE, Wu FC, Horan MA. Difficulties in measuring the effect of testosterone replacement therapy on muscle function in older men. Int J Androl. 1999 Aug;22(4):261-5. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81.
Starting date: October 2004
Ending date: March 2007
Last updated: November 29, 2007
|